Nucleophosmin (NPM) is a nucleocytoplasmic shuttling protein involved in leukemia-associated chromosomal translocations, and it regulates the alternate reading frame (ARF)-p53 tumor-suppressor pathway. Recently, it has been demonstrated that mutations of the NPM1 gene alter the protein at its C-terminal, causing its cytoplasmic localization. Cytoplasmic NPM was detected in 35% of adult patients with primary non-French-American-British (FAB) classification M3 acute myeloid leukemia (AML), associated mainly with normal karyotype. We evaluated the prevalence of the NPM1 gene mutation in non-M3 childhood AML patients enrolled in the ongoing Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP-AML02) protocol in Italy. NPM1 mutations were found in 7 (6.5%) of 107 successfully analyzed patients. NPM1-mutated patients carried a normal karyotype (7/26, 27.1%) and were older in age. Thus, the NPM1 mutation is a frequent abnormality in AML patients without known genetic marker; the mutation may represent a new target to monitor minimal residual disease in AML and a potential candidate for alternative and targeted treatments.

Cazzaniga, G., Dell'Oro, M., Mecucci, C., Giarin, E., Masetti, R., Rossi, V., et al. (2005). Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. BLOOD, 106(4), 1419-1422 [10.1182/blood-2005-03-0899].

Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype

Cazzaniga, G;BIONDI, ANDREA;
2005

Abstract

Nucleophosmin (NPM) is a nucleocytoplasmic shuttling protein involved in leukemia-associated chromosomal translocations, and it regulates the alternate reading frame (ARF)-p53 tumor-suppressor pathway. Recently, it has been demonstrated that mutations of the NPM1 gene alter the protein at its C-terminal, causing its cytoplasmic localization. Cytoplasmic NPM was detected in 35% of adult patients with primary non-French-American-British (FAB) classification M3 acute myeloid leukemia (AML), associated mainly with normal karyotype. We evaluated the prevalence of the NPM1 gene mutation in non-M3 childhood AML patients enrolled in the ongoing Associazione Italiana di Ematologia e Oncologia Pediatrica (AIEOP-AML02) protocol in Italy. NPM1 mutations were found in 7 (6.5%) of 107 successfully analyzed patients. NPM1-mutated patients carried a normal karyotype (7/26, 27.1%) and were older in age. Thus, the NPM1 mutation is a frequent abnormality in AML patients without known genetic marker; the mutation may represent a new target to monitor minimal residual disease in AML and a potential candidate for alternative and targeted treatments.
Articolo in rivista - Articolo scientifico
Scientifica
Childhood AML
English
1419
1422
Cazzaniga, G., Dell'Oro, M., Mecucci, C., Giarin, E., Masetti, R., Rossi, V., et al. (2005). Nucleophosmin mutations in childhood acute myelogenous leukemia with normal karyotype. BLOOD, 106(4), 1419-1422 [10.1182/blood-2005-03-0899].
Cazzaniga, G; Dell'Oro, M; Mecucci, C; Giarin, E; Masetti, R; Rossi, V; Locatelli, F; Martelli, M; Basso, G; Pession, A; Biondi, A; Falini, B
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/10281/14858
Citazioni
  • Scopus 137
  • ???jsp.display-item.citation.isi??? 123
Social impact